They are trying to get the max price for a buyout. It's their job to enhance shareholder equity and I am sure those on the board and management who own many shares want to bank as much money as possible like we all do so I give it perpahs Q1 2019 until I would entertain a Buy Out. Why I say this, well when I calculate the NPV and the potential CYDY can enhance my shareholder weath it is all unknown until Pro 140 is approved by FDA hence Q1 2019 is what I foresee as BLA approval.
Of course I hope for earlier, but won't bank too much on it.
Why lack of HIV indications - the BP has sufficient drugs on market and adding new ones - they do not want to cannibalize their own drugs that are so established.
Also CYDY is struggling so badly that mono therapy is at least 3-4 years away from approval (P2 and then large P3 and another confirmatory P3 and BLA + 10 months for approval)
So Pro-140 is not a threat to them for 3-4 years - they can wait or ignore and can buy the company after 2 years for tiny premium when it is derisked.
My hope to come out of red is gVHD 10 patient interim and possible collaboration
News 
Market Data 
Discover 
